Plain-English translation of NCT07348237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers studied how the medication behaved in people's bodies over time. The trial compared how the medication worked in people with severe kidney disease, people on dialysis, and people with healthy kidneys. The goal was to understand whether kidney disease changes how the medication is processed by the body.
When kidneys don't work properly, they may not clear medications from your body at the same rate as healthy kidneys do. Researchers needed to understand how this medication behaves in people with kidney disease to make sure it's safe and effective for them.
Participants received a single dose of the medication on the first day. People with end-stage kidney disease on dialysis received two doses separated by at least 14 days, to see if a second dose behaved differently. Researchers then monitored participants' blood levels over time to track how their bodies processed the medication, comparing results between the kidney disease groups and the healthy control group.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States